The Oswestry Spinal Risk Index (OSRI): an external validation study

Purpose The Oswestry Spinal Risk Index (OSRI) was recently reported as an adjunct in the management of metastatic spinal disease. Based on the tumour type and a general condition score, survivorship is predicted. We aimed to externally validate this new score. Methods We assessed the survivorship of...

Full description

Saved in:
Bibliographic Details
Published inEuropean spine journal Vol. 25; no. 1; pp. 252 - 256
Main Authors Fleming, Christina, Baker, Joseph F., O’Neill, Shane C., Rowan, Fiachra E., Byrne, Damien P., Synnott, Keith
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 01.01.2016
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Purpose The Oswestry Spinal Risk Index (OSRI) was recently reported as an adjunct in the management of metastatic spinal disease. Based on the tumour type and a general condition score, survivorship is predicted. We aimed to externally validate this new score. Methods We assessed the survivorship of 121 patients identified from a prospectively collated database in the National Spinal Injuries Unit in the Republic of Ireland. Actual survivorship was calculated according to the tumour subtype and general conditioning, according to the Karnofsky Performance Score (OSRI = Primary Tumour Pathology + (2−General Conditioning Score)). Our results were then compared to those previously published. Results 45.5 % were female ( n  = 55). The mean age at presentation was 61.5 years (range 23–85). Breast and prostate cancers were the most frequent diseases encountered. The actual survival in our cohort closely mirrored the predicted survival, according to the equation used to calculate the OSRI with an overall strong correlation found ( r  = 0.798, p  = 0.001). Conclusion We found that the OSRI is a simple to use scoring system. We found a strong correlation in our results with the predicted survivorship based on the OSRI. The OSRI can be used as a useful adjunct in the management of patient with metastatic disease of the spine.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:0940-6719
1432-0932
DOI:10.1007/s00586-014-3730-z